Enable Accessibility
Enable Accessibility
Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Design Concept
Where we work
Corporate Philosophy
Corporate Governance
Values and Corporate Governance
Board of Directors
Nomination Committee and Compensation Committee
Audit and Supervisory Committee and Internal Audit
Our Management
Charters and Reports, etc.
Risk & Crisis Management
Global Ethics & Compliance / Global Code of Conduct
Transparency Disclosures
EFPIA Disclosure Code Reports
Patient Group Disclosures
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Investigator Initiated Research
Takeda Ventures, Inc.
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Partnering with Takeda
Takeda Digital Ventures
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
Takeda Supplier Solutions Portal
Supplier Registration Process via Ariba Commerce Cloud
T-CiRA
About T-CiRA
Leaders Message
What we do
Portfolios
Projects
Inside T-CiRA
Research Achievements
Future of iPSC
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
Two centuries. Countless innovations. One vision.
Learn more
All Stories
Corporate Responsibility
Takeda's CSR
Takeda is committed to addressing the world’s biggest challenges to sustainable development over the long term.
LEARN MORE
Programs in Action
Takeda Chair in Global Child Health
Takeda Initiative for the Global Fund
Global CSR Program
Apply for Funding
Leaders Driving Change
Purpose led-Sustainability at Takeda
Patient
People
Planet
Governance
Reporting on Sustainability
TAKEDA LIFE THEATER, Embark on a journey of discovery inside the human body!
LEARN MORE
HOME
Newsroom
Statements
Share:
Newsroom
Global News Releases
Statements
In the News
Featured Topics
Corporate Materials
Social Media
Statements
Enter
All
Last 12 months
2021
2020
2019
2018
2017
2016
2015
2014
April 2022
April 1, 2022
4/1/2022
Takeda Provides Update on Status of Acquisition of Own Shares
March 2022
March 21, 2022
3/21/2022
Takeda Provides Update on Operations in Russia
March 1, 2022
3/1/2022
Takeda Provides Update on Status of Acquisition of Own Shares
February 2022
February 3, 2022
2/3/2022
European Commission Approves Vedolizumab IV for the Treatment of Active Chronic Pouchitis
February 3, 2022
2/3/2022
Takeda Provides Update on Status of Acquisition of Own Shares
January 2022
January 5, 2022
1/5/2022
Takeda Provides Update on Status of Acquisition of Own Shares
December 2021
December 1, 2021
12/1/2021
Takeda Provides Update on Status of Acquisition of Own Shares
October 2021
October 28, 2021
10/28/2021
Update on the US Development Program for the Investigational Subcutaneous Formulation of ENTYVIO vedolizumab as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
August 2021
August 11, 2021
8/11/2021
Remembering Tadataka “Tachi” Yamada
1
2
3
4
TOP
Close
